Silver Book Fact

Fact image

The present value QUALY gains associated with a new drug that by 2010 could delay disease onset by 1, 3, and 5 years. The dollar value estimates range from approximately $0.7 trillion, for a 1 year delay in Alzheimer’s disease onset for all new cases from 2010 to 2050 (QUALY valued at $100,000), to almost $4 trillion, for a 5-year delay in Alzheimer’s disease onset for all new cases between 2010 and 2050 (QUALY valued at $175,000).

Categories

  • Innovative Medical Research
  • Economic Value

Related Facts

  • Galantamine, a cholinesterase inhibitor, delays Alzheimer’s patients’ need for full-time care, with overall cost savings estimated between $323 and $4,256 per patient.  
  • A treatment that delayed the age of onset of Alzheimer’s disease by five years would reduce the proportion of Americans age 65 and older with the disease from 10% to…  
  • A large set of NIH clinical trials are assessing interventions (including dietary supplements–creatine and coenzyme Q10) that may slow the progression of Parkinson’s disease.  
  • 91 medicines are currently in development for Alzheimer’s disease.  
  • In a study of different treatments for Parkinson’s disease, results showed that the disease can be managed for up to 5 years with a reduces risk of dyskinesia.